You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科(06622.HK)治療近視加深藥品三期臨床試驗完成患者入組
阿思達克 08-02 17:03
兆科眼科(06622.HK)宣布,核心產品NVK002為期兩年的第三期臨床試驗,及同步進行的為期一年的第三期橋接臨床試驗,已分別於7月21日及28日完成患者入組。 兩項臨床試驗主要目標為評估NVK002對於治療兒童及青少年近視加深的療效及安全性。另外,兆科眼科合作夥伴VylumaInc.亦正於歐美進行NVK002第三期臨床試驗,療程為期三年,預計將於2022年底前完成,並預期於2023年向美國食品藥品監督管理局提交新藥申請。 NVK002現時的定位為全球首個經臨床驗證可治療近視加深的認可藥品,公司表示,預期兩項臨床試驗完成入組,將使公司佔據在中國開發藥物治療近視加深的領先位置。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account